Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term extension study of ABT-494 in ulcerative colitis
MOH_2017-05-21_000109Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of upadacitinib in autoimmune colitis (2 arms), sponsored by AbbVie Inc. Started Apr 2017; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-05-21_000109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-21_000109.